Conflicts Of Interest Delay Leqembi’s EU Approval
Eisai/Biogen’s Alzheimer’s drug has fallen foul of a recent court ruling over the handling of the European Medicines Agency’s experts' competing interests.
Eisai/Biogen’s Alzheimer’s drug has fallen foul of a recent court ruling over the handling of the European Medicines Agency’s experts' competing interests.